Praxis Precision Medicines (PRAX) Research & Development (2019 - 2026)

Praxis Precision Medicines' Research & Development history runs 8 years deep, the most recent figure standing at $78.0 million for Q1 2026.

• On a quarterly basis, Research & Development rose 28.26% year-over-year to $78.0 million in Q1 2026; TTM through Mar 2026 was $284.3 million, a 52.65% increase from a year earlier, with the FY2025 full-year figure at $267.1 million, up 75.26% from the prior year.
• Research & Development climbed to $78.0 million in Q1 2026 per PRAX's latest filing, from $77.5 million in the prior quarter.
• Across five years, Research & Development topped out at $78.0 million in Q1 2026 and bottomed at $17.3 million in Q3 2023.
• The 5-year median for Research & Development is $41.9 million (2024), against an average of $43.5 million.
• Across the five-year window, Research & Development plunged 51.56% in 2023 and soared 206.11% in 2024, its largest moves.
• Year by year, Research & Development stood at $28.3 million in 2022, then tumbled by 35.09% to $18.4 million in 2023, then surged by 206.11% to $56.3 million in 2024, then surged by 37.7% to $77.5 million in 2025, then grew by 0.62% to $78.0 million in 2026.
• Per Business Quant, the three latest PRAX Research & Development figures stand at $78.0 million (Q1 2026), $77.5 million (Q4 2025), and $65.8 million (Q3 2025).